BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 01:15:51 26/06/2024 pm IST | ||
| 1,160 EUR | +0.18% |
|
| Current month | +6.12% | ||
| 1 month | +7.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 1,160 | +0.18% |
| 25/24/25 | 1,158 | +0.17% |
| 24/24/24 | 1,156 | +0.43% |
| 21/24/21 | 1,151 | +0.07% |
| 20/24/20 | 1,150 | -0.23% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 01:15 pm IST
More quotesStatic data
| Product type | Certificati Bonus e Protezione parz. |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3TA7 |
| ISIN | DE000HD3TA73 |
| Date issued | 18/03/2024 |
| Strike | 1,200 $ |
| Maturity | 20/12/2024 (178 Days) |
| Parity | 1 : 1 |
| Emission price | 961 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,160 € |
|---|---|
| Lowest since issue | 910.8 € |
| Spread | 1.25 € |
| Spread % | 0.11% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Certificates
- Certificat
